{
  "data": {
    "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNZ",
    "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNZ",
    "indicator": {
      "slug": "cell-and-gene-therapy-reimbursement-rate",
      "name": "Cell and gene therapy reimbursement rate",
      "definition": "Percentage of cell and gene therapies that are reimbursed in a given country or region."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      },
      {
        "slug": "healthcare",
        "name": "Human health activities",
        "isic": "Q86",
        "is_primary": false
      }
    ],
    "region": {
      "code": "EU",
      "name": "European Union",
      "type": "bloc"
    },
    "period": {
      "start": "2023-04-01",
      "end": "2023-04-01",
      "type": "point"
    },
    "value": 42,
    "value_text": "42%",
    "unit": "percent",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "IQVIA Institute",
      "org_short_name": "IQVIA",
      "org_url": "https://www.iqvia.com",
      "org_tier": 3,
      "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios",
      "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies",
      "document_type": "press_release",
      "locator": "Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP",
      "quote": "Within Western Europe, the wealthiest countries — Luxembourg and Switzerland — reimburse fewer therapies (42%) than Germany and France, which have lower GDP per capita but reimburse 75% or more of therapies.",
      "published_date": null,
      "accessed_at": "2026-09-15",
      "license": "see-source",
      "url_status": "ok"
    },
    "verification": "verified",
    "verified_by": "seed:auto-extract-v1",
    "verified_at": "2026-09-15T22:15:46.809Z",
    "confidence": 0.9,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNZ",
      "bibtex": "@misc{iqvia2023cellkt7nnz,\n  author       = {{IQVIA Institute}},\n  title        = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNZ},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}"
    },
    "updated_at": "2026-09-15T22:15:46.809Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}